This study is being performed to determine the safety and efficacy of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain associated with Fibromyalgia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
200
Unnamed facility
Encinitas, California, United States
Unnamed facility
Garden Grove, California, United States
Clinically significant pain reduction, evidenced by a statistically significant difference between active and placebo groups in percentage of subjects who achieve a pain reduction of at least 30% at week 12 as compared to the Baseline.
Additional outcome measures will include mood alteration, sleep quality, improvement of physical functioning and relief medication usage by subjects in both groups.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
La Jolla, California, United States
Unnamed facility
Lancaster, California, United States
Unnamed facility
Murrieta, California, United States
Unnamed facility
Palmdale, California, United States
Unnamed facility
Gainsville, Florida, United States
Unnamed facility
West Palm Beach, Florida, United States
Unnamed facility
Winter Park, Florida, United States
Unnamed facility
Lexington, Kentucky, United States
...and 11 more locations